UnknownNot Applicable

ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings

Australia6,000 participantsStarted 2018-05-28

Plain-language summary

The overall goals of the ETHOS II Project are to enhance hepatitis C virus (HCV) care in drug treatment clinics and needle and syringe programs (NSPs) in New South Wales and Australia, and to develop a translational framework for subsequent establishment of HCV screening and treatment programs in drug treatment clinics and NSPs across NSW and nationally.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participant has voluntarily signed the informed consent form; * 18 years of age or older; * History of injecting drug use\*; * Recent injecting drug use (previous six months) or currently receiving OST\*. * These criteria will not apply for recruitment from residential rehabilitation centres Exclusion Criteria: * Nil

What they're measuring

Number of participants commencing anti-HCV treatment

Timeframe: Every year post enrolment for up to 3 years

Trial details

NCT IDNCT03685045

SponsorKirby Institute

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2025-01-30

Contact for this trial

David Silk, BSc

+61 2 9385 0878 dsilk@kirby.unsw.edu.au

View on ClinicalTrials.gov More Hepatitis C trials